Fonte: Cancer Immunology Research. Unidades: FCF, FMRP
Assuntos: CITOTOXICIDADE IMUNOLÓGICA, IMUNOTERAPIA, MACRÓFAGOS, FARMACOTERAPIA
ABNT
WANDERLEY, Carlos Wagner de Souza et al. PD-1/PD-L1 inhibition enhances chemotherapy induced neuropathic pain by suppressing neuroimmune antinociceptive signaling. Cancer Immunology Research, v. 10, n. 11, p. 1299–1308, 2022Tradução . . Disponível em: https://doi.org/10.1158/2326-6066.CIR-22-0003. Acesso em: 14 nov. 2024.APA
Wanderley, C. W. de S., Maganin, A. G. de M., Mendes, A. S., Silva, C. E. A., Quadros, A. U. de, Luiz, J. P. M., et al. (2022). PD-1/PD-L1 inhibition enhances chemotherapy induced neuropathic pain by suppressing neuroimmune antinociceptive signaling. Cancer Immunology Research, 10( 11), 1299–1308. doi:10.1158/2326-6066.CIR-22-0003NLM
Wanderley CW de S, Maganin AG de M, Mendes AS, Silva CEA, Quadros AU de, Luiz JPM, Silva CM de S, Silva NR, Oliveira FF, Gomes FIF, Restrepo JLJ, Hernandez CAS, Turaça F, Gabriel VL da, Pigatto GR, Nakaya HTI, Mota JM, Sousa RB, Alves Filho JCF, Cunha TM, Cunha FQ. PD-1/PD-L1 inhibition enhances chemotherapy induced neuropathic pain by suppressing neuroimmune antinociceptive signaling [Internet]. Cancer Immunology Research. 2022 ; 10( 11): 1299–1308.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1158/2326-6066.CIR-22-0003Vancouver
Wanderley CW de S, Maganin AG de M, Mendes AS, Silva CEA, Quadros AU de, Luiz JPM, Silva CM de S, Silva NR, Oliveira FF, Gomes FIF, Restrepo JLJ, Hernandez CAS, Turaça F, Gabriel VL da, Pigatto GR, Nakaya HTI, Mota JM, Sousa RB, Alves Filho JCF, Cunha TM, Cunha FQ. PD-1/PD-L1 inhibition enhances chemotherapy induced neuropathic pain by suppressing neuroimmune antinociceptive signaling [Internet]. Cancer Immunology Research. 2022 ; 10( 11): 1299–1308.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1158/2326-6066.CIR-22-0003